Floatz logo

FLUTICASONE

Recurrent Brain Neoplasm

Mayo ClinicSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Recurrent Brain Neoplasm cohort.

Asset / SponsorPhaseRating
Trebananib
National Cancer Institute (NCI)
Phase 2B
Sargramostim
Mayo Clinic
Phase 1CCC
Autologous Cytomegalovirus-Specific Cytotoxic T-Lymphocytes
M.D. Anderson Cancer Center
Phase 1/2CCC
Egfrbi-Armed Autologous T Cells
Barbara Ann Karmanos Cancer Institute
Phase 1/2CCC
Montanide Isa-51
Roswell Park Cancer Institute
Phase 1CC

View all 10 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →